Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-03 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $1.66 -8.29% 0.0% 24K
|
Health Technology
| Email alert
Add to watchlist
ath434 disease positive parkinson’s therapeutics
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 19:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100
|
Health Technology
| Email alert
Add to watchlist
BHC | $7.36 3.08% 0.0% 1.8M
|
Health Technology
| Email alert
Add to watchlist
BIIB | $234.64 0.24% 0.26% 570K
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
| Email alert
Add to watchlist
BCLI | $0.26 -6.81% -7.31% 3.7M
|
Health Technology
| Email alert
Add to watchlist
VTRS | $9.37 2.07% 1.92% 6.4M
|
Health Technology
| Email alert
Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
| Email alert
Add to watchlist
disease companies health therapeutics market
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
SNGX | $0.73 75.73% -5.49% 7M
|
Health Technology
|
| O: 32.76%
H: 0.0%
C: 0.0%
fda disease treatment clearance trial
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $9.71 -1.12% 0.0% 6.2M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GH | $26.33 4.61% 0.61% 1.1M
|
Health Services
|
| O: 1.51%
H: 3.92%
C: -1.29%
disease breast health symposium biomarker cancer therapy
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $6.19 1.81% 2.01% 900K
|
Manufacturing
|
| O: 8.68%
H: 0.0%
C: 0.0%
fda rare drug disease program
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
BIVI P | $1.68 -6.67% -6.82% 1.3M
|
Health Technology
|
| O: -70.4%
H: 0.0%
C: 0.0%
ne3107 disease alzheimer’s trial
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
CERE | $26.0 0.27% -2.0% 1.6M
|
Finance
|
| O: -0.08%
H: 5.19%
C: 1.2%
disease parkinson’s therapeutics
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
QURE | $7.14 5.31% 4.84% 740K
|
Health Technology
|
| O: 3.25%
H: 4.58%
C: -2.58%
amt-191 fda drug disease clearance application therapy
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
Published: 2023-11-28 (Crawled : 14:00) - globenewswire.com
STXS | $1.77 7.27% 0.0% 220K
|
Health Technology
| Email alert
Add to watchlist
disease health heart technology
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ATHA | $1.51 4.86% 4.64% 160K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
pharma disease symposium presentation international
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27 (Crawled : 23:00) - biospace.com/
ALDX | $2.86 3.25% 0.35% 910K
|
Health Technology
| Email alert
Add to watchlist
reproxalap drug disease food treatment eye application therapeutics response
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD G | $22.6 1.44% 0.0% 1.2M
|
Health Technology
| Email alert
Add to watchlist
acp-204 disease alzheimer’s treatment pharmaceuticals trial
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
INMB | $9.61 1.69% -1.67% 57K
|
Health Technology
|
| O: 2.0%
H: 5.24%
C: 2.29%
disease alzheimer’s authorization trial
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ICAD | $1.77 9.94% -1.13% 220K
|
Technology Services
|
| O: 0.38%
H: 0.0%
C: 0.0%
reveal disease breast year cancer risk heart
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
ANVS | $8.49 1.88% 240K
|
Health Technology
|
| O: 2.56%
H: 17.65%
C: 8.68%
disease alzheimer’s
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
SEOVF | $0.518 -2.23% 39.11% 100K
|
Health Technology
| Email alert
Add to watchlist
fda rare drug disease program
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K
|
Health Technology
|
| O: -0.03%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K
|
Health Technology
|
| O: -0.03%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Published: 2023-11-26 (Crawled : 00:00) - globenewswire.com
MESO | $1.36 -1.45% -2.94% 0
|
Health Technology
|
| O: 4.21%
H: 2.94%
C: 0.74%
rare drug disease treatment heart
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K
|
Finance
BKKT 4 | $1.88 25.33% 14.89% 4.8M
|
MGLD | $1.03 7.77% 14K
|
Manufacturing
CZOO | $0.4316 -6.52% 6.7% 65K
|
SATX | $0.4226 -1.72% 6.48% 29K
|
n/a
CCJ | $45.4 -1.13% 4.6% 3.9M
|
Non-Energy Minerals
AUMN | $0.562 0.34% 4.5% 360K
|
Non-Energy Minerals
JBL | $116.91 1.38% 4.3% 2M
|
Electronic Technology
SAIC 4 | $119.92 2.14% 4.24% 460K
|
Technology Services
CULP 4 | $5.06 -0.59% 3.95% 29K
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.